Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDD-2105 for IBS-C
NCT06319729Phase 2Not yet recruiting
- Sponsor
- Hong Kong Baptist University
- Start
- Mar 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of CDD-2105 in irritable bowel syndrome (IBS), sponsored by Hong Kong Baptist University. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
CDD-2105
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06319729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319729.